Prostasomas: search of biomarkers for the early detection of prostate cancer

  • Manuela Antonia García Instituto Tecnológico Metropolitano
  • Julieth Rueda Instituto Tecnológico Metropolitano
  • Johanna Pedroza-Díaz Instituto Tecnológico Metropolitano
Keywords: Biomarkers, Prostate Cancer, Extracellular Vesicles, Prostasomes, Proteins

Abstract

Prostate cancer is the second most diagnosed disease in men worldwide, with an increasing mortality rate in recent years. Currently, there are two early detection tests, the measurement of blood levels of prostate-specific antigen and digital rectal examination of the prostate. However, these tests do not present optimal specificity and sensitivity for their detection. Although different studies have looked for new biomarkers by means of the implementation of technologies, such as new generation sequencing, mass spectrometry, among others, the same disadvantages persist, therefore, they have not allowed their use in clinical practice; The discovery of new biomarkers for the diagnosis of prostate cancer is a challenge for the scientific community.

Prostasomes correspond to extracellular vesicles secreted by normal prostate or tumor tissue that can be detected in different fluids. Structurally, prostasomes differ from other exosomes, by their size, membrane composition and specific protein content, which makes them a potential and novel source of clinical biomarkers.

In this context, this review presents an overview of protein biomarkers, isolated from prostasomes present in different biological fluids, for the possible diagnosis of prostate cancer. For this, a systematic PubMed search was carried out for studies in proteomics for prostate cancer, with criteria such as extracellular vesicles, exosomes and prostasomes, as well as blood, urine, seminal fluid, among other biological samples.

Downloads

Download data is not yet available.

Author Biographies

Manuela Antonia García, Instituto Tecnológico Metropolitano

Estudiante de ingeniería biomédica, Facultad de Ciencias Exactas y Aplicadas, Instituto Tecnológico Metropolitano, Medellín-Colombia, manuelagarcia189035@correo.itm.edu.co

Julieth Rueda, Instituto Tecnológico Metropolitano

Estudiante de ingeniería biomédica, Facultad de Ciencias Exactas y Aplicadas, Instituto Tecnológico Metropolitano, Medellín-Colombia, ,juliethrueda188597@correo.itm.edu.co

Johanna Pedroza-Díaz, Instituto Tecnológico Metropolitano

MSc en Ciencias Básicas Biomédicas, Facultad de Ciencias Exactas y Aplicadas, Grupo de Investigación e Innovación Biomédica GI2B, Línea de Ciencias Biomédicas. Microbióloga, Instituto Tecnológico Metropolitano, Medellín-Colombia, ninipedroza@itm.edu.co

References

[1] B. Pullar and N. Shah, “Prostate cancer,” Surg., vol. 34, no. 10, pp. 505–511, Oct. 2016.
[2] J. Ferlay et al., “GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012 v1.0,” International Agency for Research on Cancer, 2012. [Online]. Available: http://publications.iarc.fr/Databases/Iarc-Cancerbases/GLOBOCAN-2012-Estimated-Cancer-Incidence-Mortality-And-Prevalence-Worldwide-In-2012-V1.0-2012.
[3] Organización Mundial de la Salud and Organización Panamericana de la Salud, “Plataforma de información en salud de las Américas,” OPS, 2017. [Online]. Available: https://www.paho.org/hq/index.php?option=com_tabs&view=article&id=2151&Itemid=3632&lang=es.
[4] A. R. Lima, M. de L. Bastos, M. Carvalho, and P. Guedes de Pinho, “Biomarker Discovery in Human Prostate Cancer: an Update in Metabolomics Studies,” Transl. Oncol., vol. 9, no. 4, pp. 357–370, Aug. 2016.
[5] Y. A. Goo and D. R. Goodlett, “Advances in proteomic prostate cancer biomarker discovery,” J. Proteomics, vol. 73, no. 10, pp. 1839–1850, Sep. 2010.
[6] R. A. Castillejos-Molina and F. B. Gabilondo-Navarro, “Prostate Cancer,” Salud Publica Mex., vol. 58, no. 2, pp. 279–284, 2016.
[7] Instituto Nacional del Cáncer, “Análisis del antígeno prostático específico (PSA) - National Cancer Institute.” [Online]. Available: https://www.cancer.gov/espanol/tipos/prostata/hoja-informativa-psa.
[8] A. Heidenreich et al., “EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease,” Eur. Urol., vol. 59, no. 1, pp. 61–71, Jan. 2011.
[9] S. Loeb and W. J. Catalona, “The Prostate Health Index: a new test for the detection of prostate cancer,” Ther. Adv. Urol., vol. 6, no. 2, pp. 74–77, Apr. 2014.
[10] M. Lazzeri et al., “Relationship of Chronic Histologic Prostatic Inflammation in Biopsy Specimens With Serum Isoform [-2]proPSA (p2PSA), %p2PSA, and Prostate Health Index in Men With a Total Prostate-specific Antigen of 4-10 ng/mL and Normal Digital Rectal Examination,” Urology, vol. 83, no. 3, pp. 606–612, Mar. 2014.
[11] D. Hessels et al., “DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer,” Eur. Urol., vol. 44, no. 1, pp. 8–16, Jul. 2003.
[12] Y. Fradet et al., “uPM3, a new molecular urine test for the detection of prostate cancer,” Urology, vol. 64, no. 2, pp. 311–315, Aug. 2004.
[13] R. Wang, A. M. Chinnaiyan, R. L. Dunn, K. J. Wojno, and J. T. Wei, “Rational approach to implementation of prostate cancer antigen 3 into clinical care,” Cancer, vol. 115, no. 17, pp. 3879–3886, Sep. 2009.
[14] M. A. Álvarez-Blanco, P. M. Escudero-de los-Ríos, and H.-T. N, “Cáncer de próstata,” Rev. Mex. Urol., vol. 68, no. 4, pp. 245–254, 2008.
[15] M. Aalberts, T. A. E. Stout, and W. Stoorvogel, “Prostasomes: extracellular vesicles from the prostate,” Reproduction, vol. 147, no. 1, pp. R1–R14, Jan. 2014.
[16] J. Nilsson et al., “Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer,” Br. J. Cancer, vol. 100, no. 10, pp. 1603–1607, May 2009.
[17] C. Zijlstra and W. Stoorvogel, “Prostasomes as a source of diagnostic biomarkers for prostate cancer,” J. Clin. Invest., vol. 126, no. 4, pp. 1144–1151, Apr. 2016.
[18] F. Saez and R. Sullivan, “Prostasomes, post-testicular sperm maturation and fertility,” Front. Biosci. (Landmark Ed., vol. 21, pp. 1464–73, 2016.
[19] G. Ronquist, “Prostasomes are mediators of intercellular communication: from basic research to clinical implications,” J. Intern. Med., vol. 271, no. 4, pp. 400–413, Apr. 2012.
[20] A. G. Utleg et al., “Proteomic analysis of human prostasomes,” Prostate, vol. 56, no. 2, pp. 150–161, Jul. 2003.
[21] K. G. Ronquist, G. Ronquist, A. Larsson, and L. Carlsson, “Proteomic analysis of prostate cancer metastasis-derived prostasomes,” Anticancer Res., vol. 30, no. 2, pp. 285–290, Feb. 2010.
[22] S. A. Melo et al., “Glypican-1 identifies cancer exosomes and detects early pancreatic cancer,” Nature, vol. 523, no. 7559, pp. 177–182, Jul. 2015.
[23] G. Tavoosidana et al., “Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer,” Proc. Natl. Acad. Sci., vol. 108, no. 21, pp. 8809–8814, May 2011.
[24] D. a Sartori and D. W. Chan, “Biomarkers in prostate cancer,” Curr. Opin. Oncol., vol. 26, no. 3, pp. 259–264, May 2014.
[25] B. O. Nilsson, L. Carlsson, A. Larsson, and G. Ronquist, “Autoantibodies to Prostasomes as New Markers for Prostate Cancer,” Ups. J. Med. Sci., vol. 106, no. 1, pp. 43–50, Jan. 2001.
[26] S. Fredriksson et al., “Protein detection using proximity-dependent DNA ligation assays,” Nat. Biotechnol., vol. 20, no. 5, pp. 473–477, May 2002.
[27] J. Gu, L. Ren, X. Wang, C. Qu, and Y. Zhang, “Expression of livin, survivin and caspase-3 in prostatic cancer and their clinical significance.,” Int. J. Clin. Exp. Pathol., vol. 8, no. 11, pp. 14034–9, 2015.
[28] S. Khan et al., “Racial differences in the expression of inhibitors of apoptosis (IAP) proteins in extracellular vesicles (EV) from prostate cancer patients,” PLoS One, vol. 12, no. 10, p. e0183122, Oct. 2017.
[29] S. Khan, J. M. S. Jutzy, J. R. Aspe, D. W. McGregor, J. W. Neidigh, and N. R. Wall, “Survivin is released from cancer cells via exosomes,” Apoptosis, vol. 16, no. 1, pp. 1–12, Jan. 2011.
[30] S. Khan et al., “Plasma-Derived Exosomal Survivin, a Plausible Biomarker for Early Detection of Prostate Cancer,” PLoS One, vol. 7, no. 10, p. e46737, Oct. 2012.
[31] K. Gabriel et al., “Regulation of the Tumor Suppressor PTEN through Exosomes: A Diagnostic Potential for Prostate Cancer,” PLoS One, vol. 8, no. 7, p. e70047, Jul. 2013.
[32] X. Huang et al., “Exosomal miR-1290 and miR-375 as Prognostic Markers in Castration-resistant Prostate Cancer,” Eur. Urol., vol. 67, no. 1, pp. 33–41, Jan. 2015.
[33] R. J. Bryant et al., “Changes in circulating microRNA levels associated with prostate cancer,” Br. J. Cancer, vol. 106, no. 4, pp. 768–774, Feb. 2012.
[34] P. Filipazzi, M. Bürdek, A. Villa, L. Rivoltini, and V. Huber, “Recent advances on the role of tumor exosomes in immunosuppression and disease progression,” Semin. Cancer Biol., vol. 22, no. 4, pp. 342–349, Aug. 2012.
[35] M. Lundholm et al., “Prostate Tumor-Derived Exosomes Down-Regulate NKG2D Expression on Natural Killer Cells and CD8+ T Cells: Mechanism of Immune Evasion,” PLoS One, vol. 9, no. 9, p. e108925, Sep. 2014.
[36] A. Gámez-Valero, S. Lozano-Ramos, I. Bancu, R. Lauzurica-Valdemoros, and F. E. Borrà s, “Urinary Extracellular Vesicles as Source of Biomarkers in Kidney Diseases,” Front. Immunol., vol. 6, p. 6, Jan. 2015.
[37] S. Principe et al., “In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine,” Proteomics, vol. 13, no. 10–11, pp. 1667–1671, May 2013.
[38] Skog et al., “Uso de microvesículas en el diagnóstico, pronóstico y tratamiento de enfermedades y afecciones médicas,” 2 446 301, 2013.
[39] A. Øverbye et al., “Identification of prostate cancer biomarkers in urinary exosomes,” Oncotarget, vol. 6, no. 30, pp. 30357–30376, Oct. 2015.
[40] R. W. Cotton and M. B. Fisher, “Review: Properties of sperm and seminal fluid, informed by research on reproduction and contraception,” Forensic Sci. Int. Genet., vol. 18, pp. 66–77, Sep. 2015.
[41] M. J. Roberts, R. S. Richards, R. A. Gardiner, and L. A. Selth, “Seminal fluid: a useful source of prostate cancer biomarkers?,” Biomarkers in Medicine, vol. 9, no. 2. Future Medicine Ltd London, UK, pp. 77–80, Feb-2015.
[42] A. Lo Cicero, P. D. Stahl, and G. Raposo, “Extracellular vesicles shuffling intercellular messages: for good or for bad,” Curr. Opin. Cell Biol., vol. 35, pp. 69–77, Aug. 2015.
[43] L. Carlsson, O. Nilsson, A. Larsson, M. Stridsberg, G. Sahlén, and G. Ronquist, “Characteristics of human prostasomes isolated from three different sources,” Prostate, vol. 54, no. 4, pp. 322–330, Mar. 2003.
[44] M. R. Kovak, S. Saraswati, S. D. Goddard, and A. B. Diekman, “Proteomic identification of galectin-3 binding ligands and characterization of galectin-3 proteolytic cleavage in human prostasomes,” Andrology, vol. 1, no. 5, pp. 682–691, Sep. 2013.
[45] A. S. Block, S. Saraswati, C. F. Lichti, M. Mahadevan, and A. B. Diekman, “Co-purification of Mac-2 binding protein with galectin-3 and association with prostasomes in human semen,” Prostate, vol. 71, no. 7, pp. 711–721, May 2011.
[46] M. J. Roberts et al., “Diagnostic performance of expression of PCA3, Hepsin and miR biomarkers inejaculate in combination with serum PSA for the detection of prostate cancer,” Prostate, vol. 75, no. 5, pp. 539–549, Apr. 2015.
[47] L. Dubois et al., “Malignant cell-derived extracellular vesicles express different chromogranin epitopes compared to prostasomes,” Prostate, vol. 75, no. 10, pp. 1063–1073, Jul. 2015.
[48] A. A. Babiker, G. Ronquist, B. Nilsson, and K. N. Ekdahl, “Overexpression of ecto-protein kinases in prostasomes of metastatic cell origin,” Prostate, vol. 66, no. 7, pp. 675–686, May 2006.
[49] J. H. Teixeira, A. M. Silva, M. I. Almeida, M. A. Barbosa, and S. G. Santos, “Circulating extracellular vesicles: Their role in tissue repair and regeneration,” Transfus. Apher. Sci., vol. 55, no. 1, pp. 53–61, 2016.
[50] J. J. Tosoian, H. B. Carter, A. Lepor, and S. Loeb, “Active surveillance for prostate cancer: current evidence and contemporary state of practice,” Nat. Rev. Urol., vol. 13, no. 4, pp. 205–215, Apr. 2016.
[51] S. P. Basourakos et al., “Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer,” BJU Int., vol. 121, no. 1, pp. 69–76, Jan. 2018.
[52] T. Pellinen et al., “ITGB1-dependent upregulation of Caveolin-1 switches TGFβ signalling from tumour-suppressive to oncogenic in prostate cancer,” Sci. Rep., vol. 8, no. 1, p. 2338, Dec. 2018.
[53] P. Gimenez-Bonafe et al., “Multidrug resistance protein 1 localization in lipid raft domains and prostasomes in prostate cancer cell lines,” Onco. Targets. Ther., vol. 7, pp. 2215–2225, Dec. 2014.
[54] J. F. Renzulli et al., “Microvesicle Induction of Prostate Specific Gene Expression in Normal Human Bone Marrow Cells,” J. Urol., vol. 184, no. 5, pp. 2165–2171, Nov. 2010.
Published
2019-01-15
How to Cite
García, M., Rueda, J., & Pedroza-Díaz, J. (2019). Prostasomas: search of biomarkers for the early detection of prostate cancer. TecnoLógicas, 22(44), 131-148. Retrieved from https://revistas.itm.edu.co/index.php/tecnologicas/article/view/1181
Section
Research Papers